The CHHiP trial randomised 3216 men with localised prostate cancer (1:1:1) to three radiotherapy fractionation schedules: 74Gy/37 fractions (f) over 7.4 weeks, 60Gy/20f/4 weeks and 57Gy/19f/3.8 weeks. Literature-based dose constraints were applied with arithmetic adjustment for the hypofractionated arms. This study aimed to derive anorectal dose constraints using prospectively-collected clinicianreported outcomes (CRO) and patient-reported outcomes (PRO) and to assess the added predictive value of spatial dose metrics.
Introduction
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in the western world, with over 1.3 million cases diagnosed in 2018 (1). For patients with localised disease, external beam radiotherapy (EBRT), brachytherapy and radical prostatectomy are established radical treatments. The CHHiP (Conventional or Hypofractionated High dose intensity-modulated radiotherapy in Prostate cancer) trial (ISRCTN97182923, CRUK/06/016) randomly assigned 3216 men to conventional fractionation (74Gy in 37 fractions (f) over 7.4 weeks) or one of two hypofractionated schedules (60Gy/20f/4 weeks or 57Gy/19f/3.8 weeks). The trial demonstrated that the hypofractionated schedule of 60Gy/20f was non-inferior to conventional fractionation for the rate of biochemical or clinical recurrence up to five years following radiotherapy (2) .
There was a low incidence of late bowel and bladder side effects for all radiotherapy schedules in CHHiP. Estimated five year cumulative grade two or worse Radiation Therapy Oncology Group (RTOG) bowel side effects occurred in 11.3-13.7% of men (2) . In addition, patient-reported outcomes (PRO) in CHHiP showed substantially lower rates of bowel bother and distress to those reported in historical trials using equivalent radiotherapy schedules (3) . This reduction in side effects may be due to improved dose conformity using intensity-modulated radiotherapy (IMRT) in CHHiP, and the application of dose constraints. The toxicity outcomes of earlier studies using conventional fractionation were used to design the CHHiP dose constraints (table S1) (4-6); dose constraints were not typically used in earlier studies.
An important question is whether further tightening of the CHHiP dose constraints would enable further reduction in toxicity. It is possible that existing constraints are optimal. The low incidence of toxicity seen in CHHiP may be explained by radiogenomic variation (7) , pre-existing co-morbidity (8) , microbiota (9) or other factors unrelated to radiotherapy dose. However, it is also possible that tighter dose constraints would reduce toxicity. Data-derived constraints for the hypofractionated schedules are particularly important for two reasons. Firstly, the arithmetic conversion to obtain dose constraints for hypofractionated schedules in CHHiP was based on the difference in total dose -no radiobiological correction for changing the fraction size from 2Gy to 3Gy occurred (10) . Consequently, the validity of these constraints needs to be established. Secondly, as the 60Gy/20f schedule is increasingly used as a new standard of care for radical radiotherapy for prostate cancer, optimal dose constraints are a clinical priority.
Most dose-volume studies use the RTOG criteria or other clinician-reported outcomes (CRO) to describe toxicity; only more recent studies have evaluated PRO (5, 11) . The QUANTEC reviews recommend using PRO to assess dose-volume relationships (12) , because PRO may be more sensitive than CRO (13) . This study aims to determine anorectal dosimetric predictors of toxicity using both CRO and PRO in CHHiP, and to assess the added predictive value of spatial dose metrics.
Methods

Study design and patient selection
A case/control methodology was used for the dosimetric analysis of late-onset radiotherapy toxicity because ≥moderate side effects were uncommon in CHHiP.
"Cases" with ≥moderate late toxicity were defined using PRO and CRO endpoints 1-5 years post-radiotherapy. Moderate or worse was chosen to represent clinicallyimportant morbidity. Toxicity data at six months after radiotherapy start were excluded as residual acute toxicity may have been present. Specific thresholds for toxicity (table   S2) were determined for each CRO and PRO endpoint, according to clinical impact. Thresholds included a maximum permitted level of each symptom prior to radiotherapy, so as to avoid erroneously attributing pre-existing symptoms to radiation damage. For the control group, patients experiencing no toxicity for the relevant endpoint over the 1-5 years post-radiotherapy were identified. Only patients with ≤2 from a possible 6 timepoints with missing data were included as controls to minimise bias from missing data.
Delineation of anorectum and collation of Dose Volume Histograms (DVH)
Dose cube data from relevant patients in the CHHiP trial were imported into VODCA (Visualisation and Organisation of Data for Cancer Analysis v5.4.1, Medical Software Solutions, Switzerland) and the anorectum was checked for outlining consistency. The superior extent of the anorectum was defined as the recto-sigmoid junction, and the inferior extent was defined as the anal verge (12, 14) (see appendix). The anorectum was then split into the anal canal, (lower 3cm), and the rectum (remaining upper portion) (14, 15) to validate dose constraints reported by Buettner et al. (15) .
Dose-volume parameters were extracted from VODCA as a relative cumulative volume. For analysis of the whole cohort, hypofractionated dose schedules were converted to 2Gy equivalent schedules (EQD2) using the Withers formula and α/β=3Gy (10) . This conversion included a bin-by-bin correction on the original DVH since the relevant normal tissue structure did not receive the full prescribed dose.
Analysis of DVH data
Univariate logistic regression: DVH
Univariate logistic regression assessed the relationship between the anorectal volume (as a continuous variable) receiving specific doses (using 1Gy dose bins) and toxicity outcomes. Multivariate logistic regression was not performed because of nonindependence of dosimetric variables. Three separate cohorts were evaluated: firstly, the full CHHiP cohort (with EQD2 conversion for patients receiving hypofractionated radiotherapy); secondly, all patients receiving hypofractionated radiotherapy (60Gy or 57Gy); and thirdly, all patients receiving conventional radiotherapy (74Gy). For the conventional fractionation analysis, univariate logistic regression evaluated the change in odds of toxicity given a 1% relative increase in volume receiving 20Gy, 30Gy, 40Gy, 50Gy, 60Gy, 65Gy and 70Gy, and for the hypofractionation analysis the volume receiving 20Gy, 30Gy, 40Gy, 50Gy, 55Gy and 60Gy. Both CRO and PRO were evaluated for the anorectum, anal canal and rectum. In view of multiple testing, a modified Bonferroni adjustment, in which p-values of less than 0.005 were considered statistically significant, was made.
Atlases of complication indices (ACI): DVH
ACI are an established method of visualising the whole DVH for a cohort of patients and relating it to toxicity outcomes (16) . The overall spread of colour across the atlas gives a good visual impression of how dose and irradiated volume relate to toxicity, hence, ACI are complementary to formal statistical modelling. Construction of the ACI is explained in the supplementary appendix (page 2).
Receiver Operating Characteristic (ROC) analysis
Area under the ROC curve (AUC) was used to derive dose-volume constraints. As above, three separate cohorts were evaluated, and toxicity outcomes were dichotomised (1=toxicity present, 0=toxicity absent). The test variable was the volume receiving a specific dose, e.g. V20Gy, and 1Gy dose intervals were tested. A ROC curve plotting 1-specificity against sensitivity was constructed for each 1Gy interval.
AUC with a 95% confidence interval lower limit >0.5 were considered statistically significant.
Both the Youden index (17) and the Closest Top Left (CtL) index (18) determined the volume constraint that best discriminated between volumes predicting for toxicity. As these gave very similar outcomes (table 1 and figure S3 ), the mean of the two indices was used as the final dose constraint. To increase the rigour of derived dose constraints, bootstrapping with replacement was used, with 1000 replicates.
Outcomes were balanced for the bootstraps, i.e. 50% cases and 50% controls were selected to improve machine learning performance. A pragmatically-selected threshold for the bootstraps was chosen: if the AUC 95% confidence interval lower limit was <0.5 in >1% of the replicates, the constraint was excluded. For the separate analyses of the smaller hypofractionated and 74Gy cohorts, this 1% threshold was relaxed to 5% due to reduced statistical power.
Analysis of Dose Surface Maps (DSM)
DSM were obtained for the anorectum for all patients with DVH. Methods used to construct DSM are described in the appendix (pages 1-2) and match those used in the analysis of RT01 (15, 19) . Metrics extracted from each DSM included the Dose Surface Histogram (DSH), the longitudinal and lateral extent of dose, and eccentricity.
As above, univariate logistic regression was used to analyse the relationship between each CRO and PRO and the four DSM metrics using the dose thresholds and EQD2 conversion described earlier.
Results
Patients and dosimetric data
The cumulative DVH for the anorectum obtained for the 1150 patients (from 40 centres) qualifying as a case or control across each CRO and PRO evaluated are shown in figures S1 and S2 (the latter according to treatment arm with CHHiP dose constraints). A wide variation in DVH shape is seen and some DVH exceed the relevant CHHiP dose constraints, especially at intermediate doses of 30-50Gy.
The numbers of patients who qualified as either "cases" or "controls" for each CRO or PRO is shown in figures 1A and B. Numbers vary considerably because of the different incidence of radiation-induced side effects. Figure 1A summarises the results of univariate logistic regression to assess the relationship between the anorectum, rectum and anal canal DVH and each CRO or PRO for all available patients (with an EQD2 correction using α/β=3Gy). For CRO, several statistically significant dose parameters were derived. There was a significant association between the anorectal volumes receiving intermediate and high doses and rectal bleeding. Odds ratios per 1% relative increase in volume increased steadily from 1.03 (95%CI:1.00-1.03, p<0.001) at 30Gy to 1.09 (95%CI:1.03-1.15, p<0.001) at 70Gy. In addition, there was a significant association between the anorectal volume receiving intermediate doses and increased bowel frequency, faecal incontinence and rectal ulceration (table S3) . Here, the volume receiving 30Gy was the strongest predictor of outcome. Overall, dose-volume relationships were weaker for PRO with only rectal urgency showing a significant association with the anorectal volume receiving 30Gy (OR 1.02 (95% CI:1.01-1.03, p=0.003) (table S4) .
Univariate logistic regression for DVH
When the anorectum was split into the rectum and anal canal, results for the rectum were very similar to the whole anorectum ( figure 1A) , which is unsurprising as the dose-volume parameters are comparable. For the anal canal, similar significant dosevolume associations with rectal bleeding and increased bowel frequency were seen to those for the anorectum and rectum. However, for other endpoints, including faecal incontinence, relationships between dose-volume and toxicity were weaker (table S5). per fraction cohort is the smallest cohort assessed. Here, the only significant relationship is between high doses and rectal bleeding. As above, no significant relationships are seen between dose and PRO.
Atlases of complication indices for DVH
A summary of ACI for the anorectum are shown in figure 2 . Collectively, the ACI corroborate findings from univariate logistic regression that higher volumes at intermediate to high doses predict side effects for rectal bleeding and higher volumes at intermediate doses predict side effects for faecal incontinence (figures 2A, 2B ).
CRO-based increased bowel frequency shows a much stronger association with dosevolume metrics than PRO-based loose stools where little association is seen ( figure   2C , 2D).
Derivation of dose constraints for DVH
ROC analysis was used to derive anorectal dose constraints for the three cohorts evaluated. 
Discussion
This case/control analysis of DVH and DSM according to the presence or absence of moderate or worse side effects has identified new dose constraints for several toxicity endpoints. To our knowledge, this is the first study to derive dose constraints for moderately hypofractionated radiotherapy. In the United Kingdom, 60Gy/20f/4 weeks is a new standard of care, with 57Gy/19f/3.8 weeks showing comparative efficacy in patients older than 75 years (20) . Modest hypofractionation is recommended in recent UK and North American guidelines (21, 22) indicating that the dose constraints derived in this study (figure 4) are clinically relevant and widely applicable to contemporary practice. Modern image-guided radiotherapy strategies permit tighter margins than those used for the majority of patients in CHHiP, as has recently been reported in the experimental arms of the CHHiP-IGRT study (23) . These tighter margins mean that meeting the target constraints we present is feasible and the proposed new anorectal constraints have recently been introduced as target (i.e. non-mandatory) constraints in both PACE-C and PIVOTALboost trials.
The specific dose levels for which constraints were derived for different symptoms are broadly consistent with the published literature. Dose constraints for rectal bleeding have been particularly well-studied and indicate that the maximum dose is the most important factor contributing to bleeding (11, (24) (25) (26) . However, as shown in our study, considerably lower doses have been shown to be important for other symptoms including bowel frequency, faecal incontinence and rectal urgency (11, 24, 27) .
Historically, the dose range of 20-40Gy has been considered less important than higher doses and one of the dosimetric trade-offs of IMRT is an increased low dose bath. Our findings indicate that meeting all dose constraints between 20Gy to 70Gy is clinically important. It is also possible that some dose constraints are conditionally relevant i.e. a dose constraint at V20 may matter less if the volume receiving high dose falls low enough.
The different dose ranges thought to be important for different side effects points to differing pathophysiology underlying side effects. Further insight is provided by the analysis of surface dose metrics. The analysis of DSM did not produce as many significant dosimetric predictors of toxicity as DVH. The most significant association was between the lateral extent of dose and rectal bleeding, which externally validates findings from the RT01 trial (19) . It has been postulated that migration of healthy cells (stem cells) from nearby regions may aid repair. This concept is reiterated with the inverse relation between eccentricity and outcome where a more eccentric shape is inversely related to toxicity. A more eccentric shape would mean a shorter distance to healthy cells in one axis. Other DSM-based correlations from RT01, including the longitudinal extent of dose and loose stools, were not observed in our study. Possible reasons include the reduced toxicity in CHHiP versus RT01 (3), and the improved conformality of radiotherapy in CHHiP causing different spatial dose patterns.
This study does not support separation of the anorectum into the anal canal and rectum in clinical practice. We found that the dose to the entire anorectum or rectum was a stronger predictor of faecal incontinence than the dose to the anal canal. The published literature with respect to the pathogenesis of radiation-induced faecal incontinence has not reached a consensus; the dose to sub-structures including the external anal sphincter and puborectalis have been suggested as important factors for incontinence (28) . Manometry studies identified both rectal and anal wall pressures as relevant (28) . Elsewhere, anal surface dose and lateral extent of anal canal dose have correlated with subjective sphincter control (15) . Finally, a recent study identified mean rectal dose and prior abdominal surgery as leading factors contributing to incontinence (29) . Overall, these data suggest that anal canal dose should not be considered in isolation as a predictor of faecal incontinence.
We found that CRO consistently identified more dosimetric predictive factors than PRO. This finding was unexpected as PRO have been shown to detect more side effects than CRO (13, 27) but may be due to the increased subjectivity of PRO.
Additionally, PRO of overall bowel bother or distress encompass a range of clinical syndromes. The EPIC questionnaire was only used by a minority of patients -this captures more radiotherapy-related bowel symptoms than the UCLA-PCI instrument used by more patients. In addition, the time period assessed in PRO questions i.e. "during the last four weeks" is typically much shorter than in CRO.
Dose cube data used to derive DVH from this analysis were derived from the planning radiotherapy scan -accumulated dose was not measured. The anorectum moves during and between radiotherapy fractions (30) ; the planning scan DVH may be a better surrogate of the true anorectal DVH during treatment than the planning scan DSH or DSM. Measurement of accumulated dose using deformable image registration of images taken during treatment should enable more precise evaluation of predictive metrics from DSM than just using the planning scan DSM (31) .
A statistically significant dose constraint does not inevitably mean it is clinically significant. Youden and CtL indices weight specificity and sensitivity equally (32) , yet the sensitivity may be more important provided Clinical Target Volume coverage is not compromised. Other limitations include use of the same α/β ratio of 3Gy across symptoms. This may be overly simplistic -other studies have used α/β=5Gy for faecal incontinence (29) . Presently we do not know how α/β ratios differ between anorectal symptoms. The uncertainty in α/β ratio might also account for the differences in constraints derived between the 2Gy cohort and the entire EQD2-corrected cohort.
For rectal pain and rectal ulceration, the number of cases (symptom events) was particularly low, which means derived constraints for rectal pain may be less robust than for other symptoms. We carefully incorporated baseline symptoms into the modelling process and our missing data analysis did not identify differences in baseline characteristics between patients included versus not included (table S7) .
However, our dosimetric modelling did not include radiogenomic variation (33) , bowel microbiota patterns (9, 34) or co-morbidities such as diabetes, hypertension, previous pelvic surgery, and inflammatory bowel disease. Finally, we acknowledge that we have not included the impact of endorectal balloons or hydrogel spacers on bowel symptoms, which provide an opportunity for further dosimetric improvements (35) .
Conclusions
Despite the low incidence of radiation-induced side effects in CHHiP, we have 
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